Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KW-6356 Phase 1 in Healthy Adults
NCT03830528Phase 1Completed
- Sponsor
- Kyowa Kirin
- Start
- Feb 2019
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of sipagladenant in Parkinson's disease (PD) (7 arms), sponsored by Kyowa Kirin. Primary endpoints: Treatment-Emergent Adverse Events at 15 days and Pharmacokinetics of plasma KW-6356 concentrations at 8 days. Started Feb 2019; status: completed.
02
Drugs
sipagladenant
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03830528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03830528.